| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.008 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.45 | 0.009 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.16 | 0.009 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |